Analysts think ANAB stock price could increase by 120%
Mar 15, 2025, 11:25 AM
2.45%
What does ANAB do
AnaptysBio, a clinical-stage biotechnology company based in San Diego, focuses on immune cell modulators and has two checkpoint agonists in Phase 2 trials for autoimmune diseases. The company went public on January 26, 2017, and employs 117 staff.
13 analysts think ANAB stock price will increase by 119.62%. The current median analyst target is $36.72 compared to a current stock price of $16.72. The lowest analysts target is $20.20 and the highest analyst target is $59.85.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.